4519.T Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 09:15):

Stats
Dzisiejszy wolumen	4.61M
Średni wolumen	2.54M
Kapitalizacja rynkowa	7 983.40B
EPS	¥45.22 ( 2024-04-24 )
Następna data zysków	( ¥52.88 ) 2024-07-25
Last Dividend	¥40.00 ( 2023-06-29 )
Next Dividend	¥0 ( N/A )
P/E	24.45
ATR14	¥4.69 (0.10%)

Wolumen Korelacja

Długi: -0.43 (neutral)

Krótki: -0.81 (strong negative)

Signal:(28.37) Be Aware. Possible trading coming up! (swing)

Chugai Pharmaceutical Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Chugai Pharmaceutical Korelacja - Waluta/Towar

-0.07
( neutral )

-0.08
( neutral )

0.03
( neutral )

-0.17
( neutral )

0.27
( neutral )

0.38
( neutral )

Chugai Pharmaceutical Finanse

Annual	2023
Przychody:	¥1 111.37B
Zysk brutto:	¥693.01B (62.36 %)
EPS:	¥197.83

FY	2023
Przychody:	¥1 111.37B
Zysk brutto:	¥693.01B (62.36 %)
EPS:	¥197.83

FY	2022
Przychody:	¥1 259.95B
Zysk brutto:	¥783.70B (62.20 %)
EPS:	¥227.64

FY	2021
Przychody:	¥999.76B
Zysk brutto:	¥661.61B (66.18 %)
EPS:	¥184.37

Financial Reports:

No articles found.

Chugai Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥0 (N/A)	¥40.00 (N/A)	¥0 (N/A)	¥40.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Chugai Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 8.15 - good (81.48%) | Divividend Growth Potential Score: 5.92 - Stable (18.36%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥0.500	2000-03-28
Last Dividend	¥40.00	2023-06-29
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	48	--
Total Paid Out	¥538.17	--
Avg. Dividend % Per Year	0.00%	--
Score	3.59	--
Div. Sustainability Score	8.15
Div.Growth Potential Score	5.92
Div. Directional Score	7.03	--

Next Divdend (Est)
(2024-10-10)

¥0 Estimate 3.74 %

Dividend Stability

0.30 Very Poor

Dividend Score

3.59

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8343.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7727.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6901.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
6262.T	Ex Dividend Knight	2023-09-28	Annually	0.00%
4974.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
4187.T	Ex Dividend Knight	2023-11-29	Semi-Annually	0.00%
3388.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
2462.T	Ex Dividend Knight	2023-11-29	Semi-Annually	0.00%
9972.T	Ex Dividend Junior	2023-11-29	Annually	0.00%
8963.T	Ex Dividend Junior	2023-12-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.315	1.500	3.70	5.55	[0 - 0.5]
returnOnAssetsTTM	0.172	1.200	4.27	5.12	[0 - 0.3]
returnOnEquityTTM	0.207	1.500	8.81	10.00	[0.1 - 1]
payoutRatioTTM	0.402	-1.000	5.98	-5.98	[0 - 1]
currentRatioTTM	5.53	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	4.21	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.937	1.500	0.351	0.526	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	18 133	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	233.57	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	197.34	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.677	1.000	2.05	2.05	[0.2 - 0.8]
operatingProfitMarginTTM	0.420	1.000	3.60	3.60	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.546	0.800	9.69	7.75	[0.5 - 2]
Total Score				8.15

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	24.46	1.000	7.63	0	[1 - 100]
returnOnEquityTTM	0.207	2.50	9.24	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	197.34	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	1.649	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	233.57	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.402	1.500	5.98	-5.98	[0 - 1]
pegRatioTTM	0.435	1.500	-0.430	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.371	1.000	3.23	0	[0.1 - 0.5]
Total Score				5.92

Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.